Manufacturer: Sanofi Aventis manufactures Telnase.


The uses of Telnase include:

Telnase is indicated for the treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children over 6 years of age.

Dosage and Administration

Telnase is for nasal administration only, and should be used regularly for optimal efficacy.

In some patients an improvement of symptoms may be apparent within the first day of treatment. However, several days of treatment may be needed for optimal benefit to be achieved.

Adults and children aged 12 years and over:

The recommended starting dose is 220 micrograms, as two sprays in each nostril once daily. Once symptoms are controlled, patients may be maintained on 110 micrograms, as one spray in each nostril, once daily.

Children aged 6 to 12 years:

The maximum recommended dose is 110 micrograms, as one spray in each nostril, once daily. In patients with more severe symptoms, a dose of 220 micrograms may be used. Once symptoms are controlled patients should be maintained on the lowest effective dose.

Children under 6 years of age:

The safety and efficacy of Telnase in children under 6 years of age have not been established, therefore use in this group of patients is currently not recommended.